Cardinal Health (NYSE: CAH) has been receiving extensive coverage in the media recently. Analysts and investment personalities like
Jim Cramer have expressed positivity towards the stock. The Company is attracting attention due to its potential in specialty growth and its potential as a potential multi-bagger. Investment banks like
Morgan Stanley, Evercore ISI, and Citigroup have raised their price targets for CAH. The company has boosted its
profit view, banking on growth in its specialty drugs unit, and lifted its full-year profit forecast, which has impressed Wall Street. Apart from that, it is striving for growth through strategic investments. The company is favored by
institutional owners and is being associated with a positive industry trend. It has launched an innovative single-patient monitoring system aiming to enhance patient care, and it is associated with solid earnings projection and increased earnings outlook. However, despite its impressive performance, the company has faced tariff headwinds. An important update is its partnership with Citius Oncology for LYMPHIR Distribution. Furthermore, the company is hailed as a better health care stock to buy compared to UnitedHealth.
Cardinal Health CAH News Analytics from Fri, 01 Nov 2024 07:00:00 GMT to Sat, 14 Jun 2025 07:43:07 GMT -
Rating 8
- Innovation 7
- Rumor -4
